Sleep Monitor First To Pre-Diagnose Sleep Apnea

Heralded as a medical-market first, Shanghai Megahealth, with the help of the Novelda company, has developed a non-contact sleep monitoring system that measures the amount and quality of sleep plus Apnea–Hypopnea Index (AHI), the medical parameter used to indicate the severity of sleep apnea. The innovative system has received China FDA approval.


According to the company, currently available sleep monitors are not accurate enough to correctly analyze sleep patterns. Diagnosing severe sleeping disorders, like sleep apnea, involves the use of bulky polysomnography equipment that is uncomfortable and may affect a patient’s sleep quality. The use of a non-contact method to measure sleep apnea was not yet a figure on the horizon. Shanghai Megahealth’s solution is the first non-contact sleep monitoring system capable of measuring sleep apnea.

Sponsored by Infosys

In Conversation with Antonio Neri, President & CEO – Hewlett Packard Enterprise & Salil Parekh, CEO – Infosys

Hear the CEOs of Infosys & HPE discuss the current crisis and how it has accelerated the need for digital transformation for their clients. Connectivity at the Edge, right mix of hybrid cloud, ability to extract data faster than ever before… these are just some of the contributions that HPE and Infosys make to our clients’ digital transformation journey.


In the US, sleep apnea syndrome affects about 4% of men and 2% of women. The complications of sleep apnea include high blood pressure, heart disease, diabetes, daytime sleepiness, and difficulty concentrating and remembering. As AHI is a medical parameter, therefore only medical grade equipment with verifiable accuracy and safety is permissible to measure this index.


 According to Wang Jian Jun, COO of Shanghai Megahealth, “Finding the right technology partner was critical to our development. We found a few sensor solutions available that can do non-contact vital signs monitoring but they all have severe limitations. Novelda however, with its unique UWB impulse radar sensor technology, has effectively overcome all these limitations. Combined with Megahealth’s own medical-grade hardware system and patented analysis algorithm, the M+ Sleep Monitoring system accurately measures respiration rate, respiration amplitude, whole body movement, sleep time, sleep cycles and AHI.”


Bjørn Åge Brandal, Novelda’s VP of sales, elaborates “The fact that Megahealth’s M+ Sleep system built on Novelda’s XeThru sensors has received medical approval is testimony not only to the accuracy of our sensor technology but also to the fact that our radar sensors are 100% safe.”


The M+ sleep monitoring solution is available now for purchase directly from Shanghai Megahealth. However, the company’s website is in Chinese with no options for English or other languages. Interested parties may want to try calling Wang Jian Jun at Shanghai Megahealth via phone at +86-21-60760258 or making contact via email: [email protected]


For more details about Novelda sensors, visit the company’s website. ~MD


Suggested Articles

Revenues overall hit $3.82 billion, up 1% from third quarter of 2019, as auto plants reopened and personal electronics revenues grew

MIT Sloan and Boston Consulting Group call for expanding organizational learning to gain better financial rewards of AI deployments

Originally a 1960s memory manufacturer, Intel wants out of NAND following the market decline in 2018